News

Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track ...
PharmExec9d
FDA Grants Fast Track Designation to Biogen’s Novel Alzheimer Disease Drug Candidate
BIIB080 marks the first antisense oligonucleotide targeting tau to enter clinical development for the treatment of Alzheimer ...
Yahoo Finance9d
Biogen’s Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer’s Disease
April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq ... Phase 1b study showed dose-dependent reductions in soluble tau protein in cerebrospinal fluid (CSF), decreases in aggregated tau ...
Zacks.com on MSN8d
BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease ...
Investing9d
Biogen’s BIIB080 gains FDA fast track for Alzheimer’s
Biogen Inc. (NASDAQ:BIIB), a prominent biotechnology ... BIIB080 is an antisense oligonucleotide (ASO) therapy targeting tau, a protein associated with neurodegeneration in Alzheimer’s disease.
Medscape2d
Novel Blood Test Could Help Diagnose, Track Alzheimer’s
A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of ...
MPR4d
Tau-Targeting Antisense Therapy for Alzheimer Disease Gets Fast Track Status
BIIB080 is an antisense oligonucleotide therapy designed to target microtubule-associated protein tau mRNA and reduce the production of tau.
Fierce Biotech1d
Atalanta laces up for clinic after RNA epilepsy candidate suppresses seizures in mice
Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake of new data showing the RNA therapy ...